A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease.

Trial Profile

A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 17 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 01 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top